TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
RNAC

Cartesian Therapeutics Inc.

Healthcare · Biotechnology

8.00$ +2.2% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Cartesian Therapeutics Inc. (RNAC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 38.0% of the shares are freely tradable; institutional investors hold 24.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 24.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 53.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 38.0%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 13.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 30Mio.

Largest Shareholders

Institutions

Institutions RNAC
Name Stake (%) Shares Change (%) Date
Squarepoint Ops LLC 7.40 2,238,486 +12,190.6 03/31/2026
FMR Inc 2.64 799,743 -41.5 03/31/2026
BlackRock Inc 1.98 599,108 -1.7 03/31/2026
Vanguard Capital Management, LLC 1.35 407,597 +0.0 03/31/2026
683 Capital Management LLC 1.09 330,000 +17.9 03/31/2026
Millennium Management LLC 1.02 309,887 +9.0 06/30/2026
Two Sigma Investments LLC 0.98 296,293 +77.1 06/30/2026

Funds

Funds RNAC
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.24 376,309 +0.0 07/31/2026
Fidelity Select Biotechnology 1.21 366,554 +0.0 07/31/2026
iShares Russell 2000 ETF 1.10 333,542 -0.6 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?